An open-label trial with TMC125 [etravirine] as part of an ART [antiretroviral therapy] including TMC114/Rtv [darunavir/ritonavir] and an investigator-selected OBR [optimised background regimen] in HIV-1 infected subjects who participated in a DUET phase III trial (TMC125-C206 or TMC125-C216).

Trial Profile

An open-label trial with TMC125 [etravirine] as part of an ART [antiretroviral therapy] including TMC114/Rtv [darunavir/ritonavir] and an investigator-selected OBR [optimised background regimen] in HIV-1 infected subjects who participated in a DUET phase III trial (TMC125-C206 or TMC125-C216).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Etravirine (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms DUET
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 26 Jun 2012 EudraCT reports actual initiation date 3 Aug 2006.
    • 22 Jun 2012 Additional locations identified as reported by as reported by European Clinical Trials Database.
    • 10 Apr 2012 Actual patient number 322 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top